Schema-Root.org logo

 

  cross-referenced news and research resources about

 Hodgkin's lymphoma

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Mon. January 15, 2018 reload page to refresh

-
lymphoma of urinary bladder is rare and can be primary (0.2% of all bladder neoplasms) or secondary (1.8% of secondary tumors of the bladder), the latter being more common. Here, we report a case each of primary and secondary lymphoma of the bladder who had undergone treatment at our hospital.
A mum and daughter struck down by cancer just five years apart have been left devastated after a third generation is now suffering with the same disease. Joanne Moss was diagnosed with blood cancer non-Hodgkin lymphoma in May 2010, aged 42, but after more than six years of treatment received the ...

Dr Dreyling, professor of medicine at the University of Munich hospital, discusses research presented at the 2017 ASH Annual Meeting likely to have a clinical impact among patients with NHL. Dr Dreyling, MD, PhD, professor of medicine at the University of Munich Hospital in Germany, is a renowned ...
For this 2-part phase 1/2 study (ClinicalTrials.gov Identifier: NCT01657331), investigators enrolled 65 patients (98% of whom had Hodgkin lymphoma; 28 patients during stage 1 and 37 during stage 2) who had failed at least 1 previous chemotherapy regimen. Stage 1 of the study was an exploratory ...
Eichenauer gave a presentation on this topic, "Nodular Lymphocyte-Predominant Hodgkin lymphoma: A Unique Disease Deserving Unique Management," during an education session at the 2017 American society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in Atlanta.

Eichenauer gave a presentation on this topic, "Nodular Lymphocyte-Predominant Hodgkin lymphoma: A Unique Disease Deserving Unique Management," during an education session at the 2017 American society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in Atlanta.
Brentuximab Vedotin/Nivolumab Combo Promising for Relapsed/Refractory Hodgkin lymphoma ... The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) demonstrated promising clinical activity in patients with relapsed/refractory Hodgkin lymphoma (HL), according to results from a ...
Treatment with the novel PD-1 inhibitor cemiplimab induced responses in half of the patients with Hodgkin lymphoma (HL) in a phase I study of patients with B-lymphoid malignancies; among patients with B-cell non-Hodgkin lymphoma (B-NHL) treated with the monotherapy, the overall response rate (ORR) ...
The addition of brentuximab vedotin (Adcetris) to frontline doxorubicin, vinblastine, and dacarbazine (A+AVD) reduced the risk of progression and death by 23% in patients with advanced-stage Hodgkin lymphoma (HL) compared with standard ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and ...
The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma (NHL), according to findings from a phase Ib study presented at the 2017 ASH Annual Meeting. Among patients with follicular lymphoma (FL), zanubrutinib induced an ...
The National Comprehensive cancer Network (NCCN) has issued updates to their guidelines for Hodgkin lymphoma, including additions to maintenance therapy options, systemic therapy options, and various treatment algorithms. In the treatment algorithms for classic Hodgkin lymphoma table, ...
The U.S. Food and Drug Administration (FDA) has agreed to review Adcetris (brentuximab vedotin) in combination with chemotherapy as a frontline treatment for patients with advanced Hodgkin's lymphoma, according to Seattle genetics. The supplemental Biologics License Application was granted priority ...
Adcetris (brentuximab vedotin) was granted a priority review to a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) to be used in combination with Adriamycin, vinblastine and dacarbazine (AVD) to treat patients with classical Hodgkin lymphoma in the frontline ...
These results can help to find new therapies against T cell non-Hodgkin's lymphoma triggered by defective immune cells. In the body T cells are usually responsible for immediately detecting and killing cancer cells. However, problems can arise when a T cell itself develops a defect in its genome, the DNA.
Cells are also equipped with such 'emergency stop' functions. They make sure that a defective cell doesn't become a tumor cell. A team has now discovered such a switch in T cells. These results can help to find new therapies against T cell non-Hodgkin's lymphoma triggered by defective immune cells.

That oncologist was Dr. Justin Markow. He delivered the news to Erskine that he had non-Hodgkin lymphoma. "It's difficult to broach that with patients but we do let them know that many patients can live for decades," Markow said. Still, it was bad news for a man who had just started retirement life. "Shock.
Hodgkin lymphoma and T/NK Cell-lymphoma-Clinical Studies: Hodgkin lymphoma Immunotherapy studies; nodular lymphocyte predominant ...
HTF MI added a new research study in its database with title 'non-Hodgkin lymphoma - pipeline Review, H2 2017' that includes detailed ...
A new 3D imaging approach for patients with early-stage Hodgkin lymphoma (HL) was better at predicting survival outcomes than standard ...
Hodgkin's lymphoma (HL)-Mechanism of action Insights, 2017″, report provides comprehensive insights of the ongoing therapeutic research ...
Radiotherapy prolonged OS among patients with all stages of nodular lymphocytic Hodgkin lymphoma, including those with B-symptoms, ...
Fremont high school seniors Hannah Leeper and Preston Reiger pose for a picture Thursday evening inside of the Milady Coffeehouse.
Radiotherapy prolonged OS among patients with all stages of nodular lymphocytic Hodgkin lymphoma, including those with B-symptoms, ...
Nonetheless, the results have convinced Takeda to suggest Adcetris as a new frontline therapy in Hodgkin's lymphoma. Seattle genetics ...
Two studies focusing on the role of the metabolic profiles of Hodgkin lymphoma and Diffuse Large B Cell lymphoma have been accepted for ...
Two variants of an adjusted regimen used in the treatment classical Hodgkin lymphoma (cHL) achieved comparable rates of complete ...
Among possible PTLD disorders, classical Hodgkin lymphoma (cHL) occurs in only 1.8% to 3.4% of cases. In addition, the incidence of PTLD ...
The phase III ECHELON-1 trial enrolled 1334 patients with stage III/IV classical Hodgkin lymphoma. All patients had not received prior ...
The recent breakthrough designation of brentuximab vedotin (Adcetris) for the first-line treatment of patients with classical Hodgkin lymphoma ...
A new research document with title 'Hodgkin lymphoma (B-Cell Hodgkin lymphoma) Global Clinical Trials Review, H2, 2017' covering ...
CD25 is found in Hodgkin's lymphoma (HL) and many types of NHL, including follicular lymphoma and diffuse large B-cell lymphoma.
Nivolumab for classical Hodgkin's lymphoma after failure of both ... with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
... local radiation) and in combination with MSD's anti-PD-1 agent Keytruda (pembrolizumab) for patients with follicular non-Hodgkin lymphoma.
Jane N. Winter, MD, professor of medicine, Feinberg school of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin ...
Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had "excellent" early relapse-free survival rates and ...
Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell ...
The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with ...
Advances in the treatment of Hodgkin lymphoma over time has led to significantly reduced all-cause mortality rates during the first decade of ...
A long-term follow-up study of immunotherapy with CAR T-cells in patients with B-cell non-Hodgkin's lymphoma with CD20-carrying B-cells ...
... clinical trial component (the "Clinical Trial"), or Stage 3, of its Hodgkin's lymphoma ("HL") test ("Telo-HLTM") validation program. Data from the ...
In relapsed classical Hodgkin lymphoma (HL), the era of therapies post-brentuximab vedotin (BV) is developing rapidly. Novel salvage ...
Jean Chen Shih and Pei Chuan Li Pei Chuan Li, left, and Jean C. Shih are researching the role of a specific enzyme in Hodgkin's lymphoma.
The gene expression-based prognostic model, RHL30, has the potential to provide insights for the selection of treatment strategies catered to ...
Jean Chen Shih and Pei Chuan Li Pei Chuan Li, left, and Jean C. Shih are researching the role of a specific enzyme in Hodgkin's lymphoma.
Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline ...
... Therapy Designation to brentuximab vedotin plus chemotherapy as first-line therapy for patients with advanced classical Hodgkin lymphoma.
Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline ...
The Venezuelan-born Carlos Izcaray, music director of the Alabama Symphony Orchestra, has been talking of his secret struggle this past year ...


 

news and opinion


 


 


 


 


schema-root.org

   human
    diseases
     cancer
      lymphoma
        hodgkin's

lymphomas:
        hodgkin's
        non‑hodgkin's